Exonic GTM brain

Exonic develops AI-designed regulatory DNA for context-aware cell and gene therapies, with prospective applications in precision medicine.

category

AI-designed genetic therapeutics

market profile

  • text: Exonic is pursuing adaptive medicine; its public site currently offers little detail about specific products or commercial arrangements.
  • text: An earlier launch described a public biological AI workflow platform and wet-lab validation; whether that model remains current is unclear.
  • text: AI-designed genetic therapies compete for validation, intellectual property and development resources alongside established genomic medicine platforms.

personas

  • title: Head of cell and gene therapy research at a potential pharma partner
    pains:
    • Needs a therapeutic payload to activate in the desired biological context
    • Must validate computational sequence designs experimentally before committing a program
  • title: Biopharma business development lead
    pains:
    • Must assess data quality and program fit before licensing a new approach
    • Needs clarity on IP ownership and development responsibilities
  • title: Computational biology researcher
    pains:
    • Needs access to useful biological AI workflows and experimental feedback
    • Must distinguish promising designs from candidates that fail in the lab

icp

  • text: Potential partners are biotech or pharmaceutical organizations developing engineered cell and gene therapy programs; partner status is inferred, not publicly confirmed.
  • text: Research teams with computational biology capacity and a need for wet-lab validation were addressed by the earlier platform launch; current availability is unverified.

message pillars

  • text: Focus on adaptive medicine as the central positioning.

objections

  • objection: Does the approach work in my biological context?
    response: Request sequence-specific experimental data, controls, and replication before evaluating a program.
  • objection: Is the platform or partnership model currently available?
    response: Ask Exonic to confirm its current offering, evidence, IP and commercial terms; the older launch may not reflect its present direction.

competitors

  • name: Deep Genomics
    why: Adjacent AI-enabled genetic medicine developer, focused on RNA biology.
  • name: Basecamp Research
    why: Biological foundation models and programmable gene insertion overlap with AI-driven genetic design.
  • name: CRISPR Therapeutics
    why: Develops gene-edited and cell therapies that can compete for therapeutic programs and partners.

influencers

  • name: Ben Brimacombe
    why: Exonic founder and CEO featured in its launch discussion.

keywords

  • AI regulatory DNA design
  • context aware gene expression
  • synthetic enhancer design
  • precision gene therapy
  • engineered cell therapy
  • biological foundation models

voice

  • scientific
  • concise
  • forward-looking

signals

  • text: A biotech team begins a cell or gene therapy program requiring context-specific gene regulation.
  • text: A research group is looking for experimental validation of AI-generated biological designs.

hiring

  • Founding Scientist (Synthetic Genomics), as advertised on YC

pricing

model: unknown

motion

unknown

channels

  • LinkedIn
  • YC directory

confidence

low

Founders

  • name: Ben Brimacombe
    title: Founder/CEO
    role: CEO
    bio: Co-founded Free2Grow, one of the largest AI voice companies in the home services vertical today. Co-led Turnpoint contract ($1.4B revenue aggregator) at Free2Grow. Columbia Computer Science and Mathematics, 2020. Published AI researcher. Led machine learning at Long Run Partners, an NYC mortgage bank. Researched ML at Numerai, the crowdsourced hedge fund ($500m+ AUM).

Back to YC companies